Institute backs development of drug to protect brain from radiotherapy

The National Cancer Institute gave Chrysalis BioTherapeutics $1.5 million for the continued development of Chrysalin, a regenerative peptide that could lessen radiotherapy-induced brain tissue damage. In clinical trials involving skin healing and bone repair, adverse events were not reported, said Darrell H. Carney, founder and CEO of Chrysalis.

View Full Article in:

American City Business Journals · Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
Actuary
Meridian Health Plan
Detroit, MI
Chief Financial Officer
B. E. Smith
Miramar, FL